TMH:dv 02/26/04 4239-66645



### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66645
Application Number	10/700,313
Filing Date	October 31, 2003
First Named Inventor	Combadiere
Art Unit	1646
Examiner Name	John D. Ulm

#### **U.S. PATENT DOCUMENTS**

O.S. I / I E I I I I I I I I I I I I I I I I				
Examiner's Initials*	Cite No. (optional)	Number	Date	Name
2		US2001/0000241	12 April 2001	Li et al.
2		US2002/0076745	20 June 2002	Li et al.
2		US2002/0099176	25 July 2002	Li et al.
~		US2002/0106742	08 Aug 2002	Samson et al.
2		US2002/0110805	15 Aug 2002	Samson et al.
2		US2002/0110870	15 Aug 2002	Samson et al.
2		US2002/0132269	19 Sept 2002	Li et al.
2		US2002/0150888	17 Oct 2002	Gray et al.
2		US2003/0023044	30 Jan 2003	Li et al.
2		5,440,021	08 Aug 1995	Chuntharapai et al.
2		6,025,154	15 Feb 2000	Li and Ruben
2	-	6,265,184	24 July 2001	Gray et al.
27		6,268,477	31 July 2001	Gray et al.
a		6,448,375	10 Sept 2002	Samson et al.
a		6,511,826	28 Jan 2003	Li et al.
~		6,528,625	04 Mar 2003	Wu et al.

EXAMINER SIGNATURE:	/	DATE CONSIDERED:	10/12/05	•

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

TMH:dv 02/26/04 4239-66645



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66645
Application Number	10/700,313
Filing Date	October 31, 2003
First Named Inventor	Combadiere
Art Unit	1646
Examiner Name	John D. Ulm

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
2		2,146,328	26 May 1994	Canada
1		WO 94/12635	09 June 1994	WIPO
2		WO 95/19436	20 July 1995	WIPO
~		WO 96/39437	12 Dec 1996	WIPO
2		WO 97/22698	26 June 1997	WIPO
2	(	WO 97/32019	04 Sept 1997	WIPO
2		WO 97/37005	09 Oct 1997	WIPO
2		WO 97/44055	27 Nov 1997	WIPO
7		WO 97/47318	18 Dec 1997	WIPO
Examiner's Initials*	Cite No. (optional)	<b>O</b> 7	THER DOCUMEN	TS
2		Alkhatib et al., "CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1," Science, 272:1955-1958, June 28, 1996		
2		Arenzana-Selsdedos et al., "HIV blocked by chemokine antagonist," Nature 383:400, October 3, 1996		
2	_	Aversa et al., "An Interleukin 4 (IL-4) Mutant Protein Inhibits both IL-4 or IL-13-induced Human Immunoglobulin G4 (IgG4) and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors," J. Exp. Med., 178: 2213-2218, December 1993		
		Carroll et al., "Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells," Science 276:273-276, April 11, 1997		

EXAMINER SIGNATURE:	1/1	DATE CONSIDERED:	10/12/05

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66645
Application Number	10/700,313
Filing Date	October 31, 2003
First Named Inventor	Combadiere
Art Unit	1646
Examiner Name	John D. Ulm

		Examiner Name	John D. Ulm
9	Cocchi <i>et al.</i> , "Identification of RAN Suppressive Factors Produced by CI 1995	08 <sup>+</sup> T Cells," Science, 270: 1	1811-1815, December 15,
2	Combadiere and Murphy, "Cloning a Chemokine Receptor," <i>The America</i> 1995 Annual Meeting no later than A	n Society for Cell Biology, A	
2	Combadiere et al., "Cloning and fun CC chemokine receptor selective for 60:147-152, July 1996	MIP-1α, MIP-1β, and RAN	NTES," J. Leuk. Biol.
2	Combadiere and Murphy, "Cloning a CC Chemokine Receptors," <i>The Ame Biology</i> , Abstract, submitted to 1996	erican Society for Biochemis Annual Meeting no later th	stry and Molecular Ian January 30, 1996
2	Combadiere et al. "Cloning, Chromo Human β Chemokine Receptor-Like November 8, 1995	Gene," DNA and Cell Biol.	, 14(8):673-680,
2	He et al., "CCR3 and CCR5 are co-r 385:645-649, February 13, 1997		
2	Kaplan et al., "Chemokines and the a August 1995 (ABSTRACT ONLY)	allergic response," Exp. Der	matol., 4(4 Pt 2):260-265,
2	Margolis et al., "Host vs. Viral Facto Mol. Path. Model April 11, 1997	/	
2	McKenzie et al., "Interleukin 13, a T monocyte and B-cell function," Proc	c. Natl. Acad. Sci. USA, 90:3	3735-3739, April 1993
2	Minty et al., "Interleukin-13 is a new immune responses," Nature, 362:248	3-250, March 18, 1993	•
2	Raport et al. "Molecular Cloning and Chemokine Receptor (CCR5) for RA 271(29):17161-17166, July 19, 1996	NTES, MIP-1 $\beta$ , and MIP-1	
2	Robinson et al., "Chemokine express RANTES and macrophage inflamma cells," Clin. Exp. Immunol., 101(3):3	sion in rheumatoid arthritis ( atory protein (MIP)-1 beta p	roduction by synovial T
2	Samson et al., "Molecular Cloning a Chemokine Receptor Gene," Biochet	nd Functional Expression of	f a New Human CC-

EXAMINER SIGNATURE:	RE	CONSIDERED: / 0/12/65	

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

4239-66645



January 1997

#### 10/700,313 **Application Number** Filing Date October 31, 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Combadiere Art Unit 1646 **Examiner Name** John D. Ulm Simmons et al., "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist," Science 276:276-279, April 11, 1997 Uguccioni et al., "Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes," Eur. J. Immunol. 25(1):64-68, January 1995 (ABSTRACT ONLY) Zimmerman et al., "Inherited Resistance to HIV-1 Conferred by an Inactivating Mutation

in CC Chemokine Receptor 5: Studies in Populations with Contrasting Clinical

Phenotypes, Defined Racial Background, and Quantified Risk," Mol. Med. 3(1):23-36.

Zurawski et al., "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction," EMBO J., 12(7):2663-2670, 1993

Attorney Docket Number

EXAMINER SIGNATURE:	DATE CONSIDERED: 10/11/	00
		•

<sup>\*</sup> Examiner: Initial il reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCEDENTE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66645-01		
Application Number	10/700,313		
Filing Date	October 31, 2003		
First Named Inventor	Combadiere		
Art Unit	1616		
Examiner Name	John D. Ulm		

<u></u>		Examiner Name John D. Ulm		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
		Choe et al., "The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates," Cell 85:1135-1148 (June 28, 1996)		
		Doranz et al., "A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors," Cell 85:1149-1158 (June 28, 1996)		
		Dragic et al., "HIV-1 entry into CD4 <sup>+</sup> cells is mediated by the chemokine receptor CC-CKR-5," Nature 381:667-673 (June 20, 1996)		
2		Kern and Dietrich, "Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution," Blut 52(4):249-254 (April 1986) Abstract Only		
2		Kuhmann et al., "Frequent Substitution Polymorphisms in African Green Monkey CCR5 Cluster at Critical Sites for Infections by Simian Immunodeficiency Virus SIVagm, Implying Ancient Virus-Host Coevolution," J Virology 75(18):8449-8460 (September 2001)		
2		Mackewicz et al., "Role of β-Chemokines in Suppressing HIV Replication," Science 274:1393-1395 (November 22, 1996)		
2		Magnani et al., "The bone marrow in murine AIDS," Br J Haematol. 84(3):539-841 (July 1993) Abstract Only		

EXAMINER SIGNATURE:	2	DATE CONSIDERED:	19/12/08
//	· · · · · · · · · · · · · · · · · · ·		

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.